PMID- 22367114
OWN - NLM
STAT- MEDLINE
DCOM- 20120731
LR  - 20220310
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 57
IP  - 6
DP  - 2012 Jun
TI  - A study on the efficacy of rebamipide for patients with proton pump 
      inhibitor-refractory non-erosive reflux disease.
PG  - 1609-17
LID - 10.1007/s10620-012-2087-6 [doi]
AB  - BACKGROUND AND AIM: Reflux symptoms in patients with non-erosive reflux disease 
      (NERD) cannot be easily controlled by treatment with proton pump inhibitors 
      (PPI). The anti-inflammatory function of rebamipide may be effective for 
      protecting the esophageal mucosa. This prospective randomized multicenter 
      placebo-controlled study was performed to clarify the efficacy of rebamipide for 
      NERD patients whose reflux symptoms were refractory to PPI treatment. METHODS: 
      One hundred forty-nine patients were enrolled on the basis of a QUEST score of 
      over 6 and absence of endoscopically proven esophageal mucosal breaks. All the 
      patients were initially administered 15 mg of lansoprazole for 4 weeks, and the 
      symptoms were then assessed using QUEST and GSRS. PPI-refractory patients were 
      randomly assigned to administration of rebamipide or placebo t.i.d. for 4 weeks. 
      RESULTS: Three of the 149 patients were lost to follow-up, and 60 among the 
      remaining 146 patients were found to be PPI-refractory. Among these 
      PPI-refractory patients, 31 were randomly assigned to a rebamipide group and 29 
      to a placebo group. At the end of drug administration, the QUEST and GSRS scores 
      did not differ between the rebamipide and placebo groups, although a 
      significantly higher proportion of patients in the rebamipide group showed 
      amelioration of abdominal pain and diarrhea. CONCLUSION: Administration of 
      rebamipide cannot effectively control reflux symptoms in NERD patients whose 
      symptoms are refractory to PPI therapy.
FAU - Adachi, Kyoichi
AU  - Adachi K
AD  - Department of Clinical Nursing, Shimane University Faculty of Medicine, Izumo 
      City, Shimane, Japan. kadachi@med.shimane-u.ac.jp
FAU - Furuta, Kenji
AU  - Furuta K
FAU - Miwa, Hiroto
AU  - Miwa H
FAU - Oshima, Tadayuki
AU  - Oshima T
FAU - Miki, Masaharu
AU  - Miki M
FAU - Komazawa, Yoshinori
AU  - Komazawa Y
FAU - Iwakiri, Katsuhiko
AU  - Iwakiri K
FAU - Furuta, Takahisa
AU  - Furuta T
FAU - Koike, Tomoyuki
AU  - Koike T
FAU - Shimatani, Tomohiko
AU  - Shimatani T
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120226
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Quinolones)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - LR583V32ZR (rebamipide)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alanine/*analogs & derivatives/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - *Drug Resistance
MH  - Esophageal pH Monitoring
MH  - Esophagoscopy/methods
MH  - Female
MH  - Follow-Up Studies
MH  - Gastroesophageal Reflux/*diagnosis/*drug therapy
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Quinolones/*therapeutic use
MH  - Recurrence
MH  - Reference Values
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/03/01 06:00
MHDA- 2012/08/01 06:00
CRDT- 2012/02/28 06:00
PHST- 2011/11/04 00:00 [received]
PHST- 2012/02/06 00:00 [accepted]
PHST- 2012/02/28 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/08/01 06:00 [medline]
AID - 10.1007/s10620-012-2087-6 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2012 Jun;57(6):1609-17. doi: 10.1007/s10620-012-2087-6. Epub 2012 
      Feb 26.